<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268071</url>
  </required_header>
  <id_info>
    <org_study_id>2014-001773-14</org_study_id>
    <nct_id>NCT02268071</nct_id>
  </id_info>
  <brief_title>Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)</brief_title>
  <official_title>Arrêt du Traitement Antihypertenseur Chez Les Patients Hypertendus Suivis en Médecine Générale / Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care: The STOP-Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The STOP-Trial is a prospective multicenter nonrandomized open study on grade I hypertension,&#xD;
      performed by General practitioners.&#xD;
&#xD;
      The study will be conducted in parallel in the Clinical Investigation Center Plurithematic&#xD;
      (CIC-P)1433 of Nancy (the study coordinating center) by the general practitioners&#xD;
      investigators of the CIC-P.&#xD;
&#xD;
      The main purpose of the study is to determine the factors associated with the rate of&#xD;
      patients remaining normotensive one year after stopping their antihypertensive monotherapy or&#xD;
      low dose dual therapy:&#xD;
&#xD;
        -  white coat hypertension&#xD;
&#xD;
        -  primary diagnosis by home blood pressure measurements (HBPM) /ambulatory blood pressure&#xD;
           measurements (ABPM) /clinical measure&#xD;
&#xD;
        -  initial blood pressure level&#xD;
&#xD;
        -  compliance&#xD;
&#xD;
        -  therapeutic class versus others&#xD;
&#xD;
        -  age&#xD;
&#xD;
        -  gender&#xD;
&#xD;
        -  weight variation&#xD;
&#xD;
        -  modification of lifestyle&#xD;
&#xD;
        -  concomitant treatments and associated substances&#xD;
&#xD;
        -  ...&#xD;
&#xD;
      The primary endpoint will be the rate of normotensive patients at one year (i.e. HBPM values&#xD;
      &lt;135/85 mmHg).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HBPM should be performed by the patients twice a day for 7 consecutive days before each visit&#xD;
      (ESH protocol), using a device clinically tested (ESH/international protocol).&#xD;
&#xD;
      At baseline (visit 1), for the patients included, the antihypertensive treatment will be&#xD;
      stopped in 3 consecutive days (half dose then interruption), over a maximum period of 12&#xD;
      months corresponding to the length of the participation and the monitoring of the patients.&#xD;
&#xD;
      Follow-up visits at day 30 (visit 2), day 90 (visit 3), day 180 (visit 4), day 270 (visit 5)&#xD;
      and day 360 (visit 6). Will be performed at each visit:&#xD;
&#xD;
        -  Calculation of the average of HBPM values by the investigator&#xD;
&#xD;
        -  Measurements of office blood pressure (average of 3 consecutive measurements)&#xD;
&#xD;
        -  SF 36 scale at baseline (visit 1) and day 360 (visit 6)&#xD;
&#xD;
        -  During follow-up, the investigator will be free at any time to reintroduce an&#xD;
           antihypertensive treatment if the average of HBPM values is greater than or equal to&#xD;
           135/85 mmHg on two consecutive visits, or greater than or equal to 155/95 mmHg&#xD;
           regardless of the visit and regardless of the office blood pressure level.&#xD;
&#xD;
      At the end of study, the recovery of an antihypertensive treatment by the patients will be&#xD;
      left to the discretion of the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 10, 2015</start_date>
  <completion_date type="Actual">October 21, 2020</completion_date>
  <primary_completion_date type="Actual">October 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of normotensive patients at 1 year (i.e HBPM &lt;135/85 mmHg)</measure>
    <time_frame>At 12 months after antihypertensive treatment interruption</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of normotensive patients at 3 months (i.e HBPM &lt;135/85 mmHg)</measure>
    <time_frame>At 3 months after antihypertensive treatment interruption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of normotensive patients at 6 months (i.e HBPM &lt;135/85 mmHg)</measure>
    <time_frame>At 6 months after antihypertensive treatment interruption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of normotensive patients at 9 months (i.e HBPM &lt;135/85 mmHg)</measure>
    <time_frame>At 9 months after antihypertensive treatment interruption</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the quality of life scale (part of SF36)</measure>
    <time_frame>Change from baseline to 12 months after antihypertensive treatment interruption</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Hypertensive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence</intervention_name>
    <description>For patients with average of HBPM values &lt;135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)</description>
    <arm_group_label>Hypertensive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory patient above 18 years old.&#xD;
&#xD;
          -  Grade I hypertension at diagnosis.&#xD;
&#xD;
          -  Hypertension diagnosed and treated (whatever is its seniority and for at least 6&#xD;
             months) by antihypertensive drug.&#xD;
&#xD;
          -  Controlled hypertension (Clinical BP &lt; 140/90 mmHg) or uncontrolled hypertension&#xD;
             (Clinical BP &gt; or equal to 140/90 mmHg) without modification of treatment for at least&#xD;
             6 months, by a monotherapy or a low dose dual therapy.&#xD;
&#xD;
          -  HBPM values &lt; 135/85mmHg (in order to exclude masked hypertension).&#xD;
&#xD;
          -  Patient having signed the informed consent form.&#xD;
&#xD;
          -  Patient affiliated to a national insurance scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal cardiovascular history and/or necessity to take the antihypertensive&#xD;
             treatment for another reason than hypertension (heart failure, migraine, peripheral&#xD;
             arterial disease, coronary heart disease, stroke…).&#xD;
&#xD;
          -  Target organ damage (evidence of ventricular hypertrophy by ECG or cardiac echography&#xD;
             and/or proteinuria and/or pathological micro-albuminuria presence showing a&#xD;
             nephropathy, in the last year).&#xD;
&#xD;
          -  Poorly compliant patient, whose score of Girerd questionnaire is equal to or greater&#xD;
             than 3.&#xD;
&#xD;
          -  Existence of a progressive disease likely to impact on the life expectancy in a short&#xD;
             term.&#xD;
&#xD;
          -  Existence of a documented atrial fibrillation (contraindication of HBPM).&#xD;
&#xD;
          -  Patient under a legal protection measure.&#xD;
&#xD;
          -  Chronic alcohol or drug abuse, regular intake of vasopressor effect substances&#xD;
             (licorice,cocaine,...).&#xD;
&#xD;
          -  Current known pregnancy or project of pregnancy within one year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc BOIVIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation Clinique Plurithématique/INSERM/CHU de Nancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cabinet de groupe Dr Birgé</name>
      <address>
        <city>Boulay</city>
        <zip>57220</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de groupe Dr BAUDOIN</name>
      <address>
        <city>Bouzonville</city>
        <zip>57320</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de groupe Dr Gries</name>
      <address>
        <city>Dettwiller</city>
        <zip>67490</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Di Patrizio</name>
      <address>
        <city>Dombasle Sur Meurthe</city>
        <zip>54110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet médical Dr Bouché</name>
      <address>
        <city>Dombasle Sur Meurthe</city>
        <zip>54110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet médical du Dr Chevillard</name>
      <address>
        <city>Dombasle Sur Meurthe</city>
        <zip>54110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maison de santé Dr Millet-Malingrey</name>
      <address>
        <city>Gondrecourt Le Chateau</city>
        <zip>55130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maison de Santé Pluridisciplinaire de GROSTENQUIN</name>
      <address>
        <city>Grostenquin</city>
        <zip>57660</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de groupe Dr Rougerie</name>
      <address>
        <city>Hatten</city>
        <zip>67690</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Plane</name>
      <address>
        <city>Jarville La Malgrange</city>
        <zip>54140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet médical prof Boivin</name>
      <address>
        <city>Laxou</city>
        <zip>54520</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr LARQUE</name>
      <address>
        <city>Le Palais-sur-Vienne</city>
        <zip>87410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de groupe Dr Faure Christian</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Dr Bleynie</name>
      <address>
        <city>Limoges</city>
        <zip>87100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Poyeton</name>
      <address>
        <city>Neufchateau</city>
        <zip>88300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Dr Delage</name>
      <address>
        <city>Nexon</city>
        <zip>87800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de groupe Dr Masson,</name>
      <address>
        <city>Remilly</city>
        <zip>57580</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de groupe en pôle de santé</name>
      <address>
        <city>Revigny-sur-Ornain</city>
        <zip>55800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Louyot-Keller</name>
      <address>
        <city>Saint-Avold</city>
        <zip>57500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet médical du Dr Carrier</name>
      <address>
        <city>Saint-Max</city>
        <zip>54130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maison de Santé du Neuhof</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>cabinet de groupe Dr Steyer</name>
      <address>
        <city>Talange</city>
        <zip>57525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique module plurithématique 1433 Inserm/CHRU de Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>cabinet du Dr Gerard</name>
      <address>
        <city>Vicherey</city>
        <zip>88170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Jean-Marc BOIVIN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Stopping antihypertensive treatment</keyword>
  <keyword>Primary care</keyword>
  <keyword>White coat hypertension</keyword>
  <keyword>Masked Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

